Correlation Between PET and Advanced MRI in Multiple Sclerosis

Completed

• Conditions: Multiple Sclerosis

• Registration Number: NCT02869360
• Lead Sponsor: University of British Columbia

Brief Summary

Traditional Magnetic Resonance Imaging (MRI) in Multiple Sclerosis (MS) has enabled clinicians to measure disease activity but there are inherent limitations. Clinical/radiographic dissociation can be seen in some patients and the abnormalities are not specific.

This pilot study is an opportunity to determine the relationship between quantitative advanced MRI measures and OCT with PET measurements of microglial activation and myelin health.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-08-12
• Study First Submitted QC: 2016-08-12
• Study First Posted: 2016-08-16
• Study Start: 2016-10
• Status Verified: 2019-10
• Primary Completion: 2019-10-02
• Study Completion: 2019-10-02
• Last Update Submitted: 2019-10-02
• Last Update Posted: 2019-10-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

• Diagnosed with Multiple Sclerosis according to the 2011 McDonald criteria.
• Aged 18 to 60
• High or mixed affinity binder to rs6971 TSPO polymorphism

Read More

Exclusion Criteria

• Pregnant or breastfeeding
• Suffering from an unstable medical condition
• Have a neurological or ocular disorder other than MS
• Any contra-indications to MRI

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Whole Brain PBR28 binding	Baseline

Secondary Outcome Measures

Name	Time	Method
Myelin Water Imaging	Baseline
Optical Coherence Tomography (RNFL thickness)	Baseline
Lesional PiB binding	Baseline
MR Spectroscopy (Total NAA, NAA/Cr, mI)	Baseline

Trial Locations

Locations (1)

MS Clinical Trials Group - UBC; 🇨🇦 Vancouver, British Columbia, Canada